{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 20 of 122', 'Demonstrating a beneficial effect on quality of life and health utility of treatment with', 'AR101 will be informative to certain treatment decision-makers, including payers. However,', 'assessment of HRQOL can be complex for infrequent episodic conditions such as peanut', 'allergy. Food allergy HRQOL is unusual because it is not characterized by daily or frequent', 'symptoms that would allow patients to perceive changes in their health status; rather, it is', 'characterized by beliefs and expectations about the risk of anaphylaxis occurring due to', 'unpredictable accidental exposures and the expected benefits of interventions that reduce this', 'risk. Experiencing an HRQOL benefit from treatment is entirely dependent on patient (and', 'parent/caregiver) knowledge that they have been receiving an active treatment and have been', 'successfully desensitized to the food allergen in question.', 'An open-label study of HRQOL of patients on standard of care alone and their', 'parents/caregivers will enable a more real-world comparison of treatments than a blinded', 'study. In a blinded study setting, patients in both treatment groups would be required to', 'follow the same study site visit schedule, which is necessarily frequent during up-dosing with', 'food allergens to safely achieve the desired level of desensitization. As this visit frequency is', 'much higher than real-world standard of care practice, it could significantly affect patient and', 'parent/caregiver responses to questionnaires. In an open-label study, the visit schedule for', 'patients receiving standard of care alone can be less frequent and would more closely align', 'with real-world standard of care practice. Therefore, an open-label study design is preferred', 'when assessing the real-world impact of AR101 treatment versus standard of care on', 'HRQOL.', 'Additionally, previous studies have shown that the DBPCFC also influences HRQOL,', \"because the information it imparts helps reduce uncertainty about the status of the patient's\", 'allergy and may reduce anxiety about their ability to manage an allergic reaction arising from', 'accidental exposure (Franxman, 2015; Soller, 2014). As a DBPCFC is not part of the', 'diagnostic pathway for peanut allergy, the ARC009 eligibility criteria include a range of', 'other relevant clinical and patient factors. However, all subjects will have an open-label food', 'challenge (OLFC) approximately 12 months after randomization to study treatment (AR10', 'or standard of care alone). Because approximately 20% of children are estimated to outgrow', 'their peanut allergy and periodic re-evaluations are recommended (Sampson, 2014;', 'Skolnick, 2001), the OLFC results will be used to confirm peanut allergy for subjects who', 'complete 18 months of standard of care alone as part of the eligibility to receive AR101 in an', 'open-label follow-on study.', 'HRQOL outcomes have been assessed in randomized, double-blind, placebo-controlled', 'studies of AR101, including ARC003 (PALISADE), ARC007 (RAMSES), and ARC010', '(ARTEMIS), and in their open-label follow-on studies. However, ARC009 is anticipated to', 'yield more meaningful HRQOL results and to better reflect the true-life patient/parent', '(caregiver) experience of AR101 treatment in combination with standard of care compared', 'with standard of care alone, and thus will provide relevant HRQOL evidence for treatment', 'decision-makers.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 21 of 122', '2', 'STUDY OBJECTIVES', '2.1', 'Primary Objective', 'To assess proxy- and self-reported disease-specific HRQOL of peanut-allergic', 'subjects aged 4 to 17 years, inclusive, receiving AR101 in combination with standard', 'of care versus standard of care alone for approximately 18 months', '2.2', 'Secondary Objectives', 'Safety and tolerability of AR10', 'To characterize changes over the course of the study in the following:', 'Disease-specific HRQOL of parents/caregivers', 'Relationship between clinical efficacy of AR101 (change in level of sensitization to', 'peanut allergen) and HRQOL of subjects and parents/caregivers', '2.3', 'Exploratory Objectives', 'To assess the following:', 'Self-reported assessments of control and confidence; reassurance, worry, and severity', 'of allergic reactions based on food challenge outcomes; and overall HRQOL', 'Changes in nondisease-specific measures of HRQOL, anxiety, and depression in', 'subjects and parents/caregivers', 'Health state utility estimates for economic analysis', 'Changes in peanut skin prick test (SPT) mean wheal diameters associated with', 'AR101 treatment', 'Changes in control of pre-existing concomitant atopic disease (asthma, allergic', 'rhinitis, atopic dermatitis)', 'Relationship between basophil activation, clinical efficacy of AR101, and changes in', 'HRQOL', 'AR101 treatment experience among subjects and parents/caregivers', '3', 'INVESTIGATIONAL PLAN', '3.1', 'Overall Study Design and Plan: Description', 'This is a phase 3b, randomized, open-label, European study of the HRQOL of AR101 in', 'combination with standard of care (AR101 herein) compared with standard of care alone in', 'approximately 200 peanut-allergic subjects aged 4 to 17 years, inclusive. Standard of care', 'includes avoidance of peanuts/peanut-containing foods, and education on recognition and', 'management of allergy symptoms and appropriate use of rescue medications (eg, epinephrine', 'auto-injectors). HRQOL of parents/caregivers will also be assessed. The safety and', 'tolerability of AR101 will be evaluated.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 22 of 122', 'Eligible subjects will be randomly assigned 2:1 to AR101 treatment or standard of care', 'alone. Randomization will be stratified by age group (4-12 years and 13-17 years). Subjects', 'in both treatment groups and their parents/caregivers will have disease-specific and', 'nondisease-specific HRQOL assessments at screening and periodically thereafter.', 'Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before', 'exiting (completing) the study: initial dose escalation, up-dosing, and maintenance. Subjects', 'receiving standard of care alone will have approximately 18 months of observation before', 'exiting (completing) the study. Subjects in both treatment groups will have a graded OLFC', 'up to a maximum single highest dose of 1000 mg of peanut protein (2043 mg cumulative),', 'approximately 12 months after randomization.', 'AR101 Treatment Group', 'Initial dose escalation: Subjects randomly assigned to AR101 treatment will begin with a', 'stepwise dose escalation of AR101 (up to 5 single doses of 0.5, 1, 1.5, 3, and 6 mg)', 'administered at 20- to 30-minute intervals as tolerated at the study site.', 'Subjects who tolerate at least 3 mg of AR101 on day 1 will return to the study site on', 'day 2 to receive a single confirmatory 3 mg dose under direct observation. Subjects', 'who tolerate the 3 mg confirmatory dose with no or mild symptoms that are not', 'dose-limiting will begin the up-dosing period.', 'Subjects who do not tolerate at least 3 mg of AR101 on day 1 or day 2 will stop', 'AR101 treatment and discontinue early from the study.', 'Up-dosing: The up-dosing period will be approximately 6 months (22-40 weeks). Dose', 'escalation will occur approximately every 2 weeks. Daily AR101 doses during up-dosing', 'will be 3, 6, 12, 20, 40, 80, 120, 160, 200, 240, and 300 mg/day. The first dose of AR101 at', 'each new dose level will be administered under direct observation at the study site; the', 'remaining doses at each dose level will be administered daily at home as tolerated. Subjects', 'able to tolerate 300 mg for 2 weeks will begin the maintenance period. Subjects unable to', 'tolerate 300 mg/day for 2 weeks within 40 weeks of up-dosing will stop AR101 treatment', 'and discontinue early from the study.', 'Maintenance: Subjects will continue AR101 daily dosing at 300 mg/day for an additional', '12 months (52 weeks) with study site visits every 4 weeks. After at least 6 months (up to', '7 months) of maintenance treatment (approximately 12 months after randomization/first dose', 'of AR101), subjects will have a graded OLFC up to a maximum single highest dose of', '1000 mg of peanut protein (3, 10, 30, 100, 300, 600, 1000 mg [2043 mg cumulative]).', 'Subjects who tolerate 1000 mg of peanut protein (2043 mg cumulative) at the OLFC', 'will continue AR101 daily at 300 mg/day and will have the option to consent for', 'a real-world peanut challenge (RWPC) within 4 weeks (preferably within 1 week)', 'after the OLFC. During the RWPC, subjects will eat a food containing 500 to 600 mg', 'of peanut protein under direct observation at the study site. Subjects who complete']", "completion": ""}